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Purpose. The purpose of this work was to determine the jejunal per-
meability of cyclosporin A (CsA) in humans and whether formulation
variables modulate the effects of P-glycoprotein (P-gp) on the per-
meability of CsA in Caco-2 cells.
Methods. A solution containing CsA, phenylalanine, propranolol,
polyethyleneglycol (PEG) 400, and PEG 4000 was perfused through
a 10-cm jejunal segment in 12 subjects. Caco-2 transport studies were
performed using previously reported methodology.
Results. The mean Peff (±SD) of CsA in humans was 1.65 (0.53). The
mean permeabilities for phenylalanine, propranolol, and PEG 400
were 4.54 (2.39), 2.90 (1.28), and 0.83 (0.51) × 10−4 cm/s, respectively.
The presence of surfactants significantly decreased the permeabilities
of CsA in both directions in Caco-2 cells.
Conclusions. The results suggest that the effects of surfactants via
micellar solubilization and inhibition of P-gp efflux on CsA transport
in Caco-2 cells are significant. CsA can rightly be classified as a low
solubility-high permeability Class II BCS drug and its highly variable
absorption from Sandimmune oral formulations is the result of poor
dissolution characteristics.
KEY WORDS: intestinal permeability; P-glycoprotein; cyclosporin
A; biopharmaceutic classification system; Caco-2 cell culture.
INTRODUCTION
Cyclosporin A (CsA) is a neutral, hydrophobic cyclic
peptide consisting of 11 amino acids. CsA has been widely
used as a potent immunosuppressant to prevent organ rejec-
tion after kidney, liver, and heart allogeneic transplantation.
It has also been used in the treatment of autoimmune dis-
eases, such as rheumatoid arthritis, uveitis, and psoriasis. Be-
cause of its poor solubility in water, ∼4 g/mL (1), intrave-
nous and oral dosage forms of CsA contain surfactants. The
pharmacokinetics of Sandimmune, an oral formulation of
CsA, in healthy volunteers have been reported (2,3) and can
be described by a two-compartment model with zero-order
absorption. Although CsA has a high octanol–Ringer’s par-
tition coefficient of 991, the absorption from the gastrointes-
tinal tract is incomplete and variable. The oral bioavailability
is approximately 30% from a Sandimmune oral formulation
with wide inter- and intrasubject variability (4). Several fac-
tors have been suggested as possible determinants of the low
and variable oral bioavailability of CsA. These include a low
permeability to the intestinal membrane, poor dissolution
characteristics, extensive metabolism by cytochrome P-450
3A4 (CYP3A4) in both liver and gut (5,6), effect of P-
glycoprotein (P-gp)-mediated drug efflux (7), and the influ-
ences of intake of food and concomitant medications (8,9).
Some reports suggest that there might be an absorption win-
dow for CsA in the upper small intestine (10). However, the
mechanism of absorption of CsA, its intrinsic permeability to
the intestinal membrane in humans and the underlying cause
of its highly variable bioavailability have not been fully ad-
dressed.
Intestinal permeability is a key factor in determining
overall absorption of orally administered drugs. The determi-
nation of effective intestinal permeabilities of drugs in hu-
mans has been facilitated by recent innovations such as the
Loc-I-Gut segmental jejunal perfusion system (11). The ad-
vantages of this perfusion system include minimizing leakage
of proximal and/or distal contents into the test segment and of
drug perfusate out of it as well as allowing perfusion to be
carried out at physiologic flow rates with a segment of known
length (10 cm). Furthermore, this system has been shown to
provide higher and more consistent recovery and a mass bal-
ance that is expected from the disappearance of drug from the
intestinal lumen and its appearance in plasma (11,12). In this
report we describe the permeability of CsA in human subjects
estimated from segmental jejunal perfusion studies. Consis-
tent with previously reported standard procedures, the pres-
ent permeability studies included marker compounds such as
propranolol, phenylalanine, and polyethyleneglycol (PEG)
400 that are absorbed to varying degrees and by different
pathways (13,14), and were used as reference compounds in
order to determine both intra-subject and inter-subject vari-
ability.
Caco-2 cell cultures have been widely used to investigate
absorption mechanisms of several classes of drugs (15,16).
These studies indicate that the evaluation of effects of formu-
lation variables such as surfactants on P-gp efflux mechanisms
in Caco-2 cells may provide useful information regarding CsA
absorption characteristics in humans. Thus, in this report we
also describe the results of the effects of surfactants and in-
hibitors of P-gp on permeability of CsA in Caco-2 cells. The
objective of these studies involves the evaluation of the in-
trinsic permeability of CsA in the two models and to elucidate
the role of P-gp efflux mechanisms in determining overall
absorption of the drug. A secondary and important objective
of these studies is to extrapolate these findings to absorption
characteristics in humans in an attempt to explain the highly
variable oral bioavailability of CsA.
MATERIALS AND METHODS
Materials
USP grade l-phenylalanine was obtained from Twin
Laboratories Inc. (Ronkonkoma, NY, USA). Propranolol
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HCl (SoloPak, IV injection) was purchased from SoloPak
Laboratories Inc. (Elk Grove Village, IL, USA). (mebmt--
3H) CsA with a specific activity of 6 Ci / mmol was from
Amersham Company. CsA (Sandimmune IV solution) was
purchased from Sandoz (East Hanover, NJ, USA). Cremo-
phor EL (polyoxyethylene 35 castor oil) and Cremophor
RH40 (polyoxyethylene 40 castor oil) were obtained from
BASF (Mount Olive, NJ, USA). d-alpha tocopheryl polyeth-
ylene glycol 1000 succinate (TPGS) was from Eastman. Dul-
becco’s modified Eagle’s medium, D-glucose, fetal bovine se-
rum, nonessential amino acids, L-glutamine, Na-pyruvate,
and penicillin (100 U/mL)/streptomycin (100 g/mL) was ob-
tained from Gibco BRL (Grand Island, NY, USA). PEG 400,
1000, 1500, and 4000 were obtained from Union Carbide
Chemicals and Plastic Company, Inc. (Danbury, CT, USA).
EcoLite(+) scintillation cocktail was from ICN Company.
Midazolam (intravenous injection) was purchased from
Roche Pharmaceuticals (Nutley, NJ, USA). Fentanyl (intra-
venous injection), xylocaine and simethicone were USP or NF
grade. Tris hydrochloride, glycerol, ethylenediaminetetraace-
tic acid, phenylmethylsulfonyl fluoride, MES, HEPES, quin-
idine, progesterone, chlorpromazine HCL, and verapamil
HCL were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). Mannitol, NaH2PO4·H2O, Na2HPO4, glucose,
KCl, and NaCl of USP or NF grade were used to prepare
perfusate solutions and were purchased from Spectrum
Chemical Mfg. Corp. (Gardena, CA). CsA (batch 92359.02)
for preparation of standards for high-performance liquid
chromatography (HPLC) and for permeability studies in rats
and CaCo-2 cells was obtained from Sandoz (East Hanover,
NJ). HPLC standards for l-phenylalanine and dl-propranolol
were purchased from Sigma Chemical Co. (St. Louis, MO,
USA). All solvents used in the assays were of HPLC grade.
All other chemicals were either HPLC or analytical grade.
Intestinal perfusions in humans were performed with a
multi-channel tube designed for study of absorption and se-
cretion in the small intestine in humans (Loc-I-Gut™, Nolato
AB, Sweden; Ref. 11). It contains six channels and two latex
balloons separated by 10 cm to create the segmental perfusion
site. Presterilized cell tissue culture inserts with Cyclopore
membrane (25 mm diameter and 3-m pore size) as well as
tissue culture treated polystyrene 6-well plates were from Fal-
con (Lincoln Park, NJ, USA).
Caco-2 Cells
Caco-2 cells (ATCC HTB37, Manassas, VA, USA) were
routinely maintained in Dulbecco’s modified Eagle’s medium
containing 4.5 g/l D-glucose, 10% fetal bovine serum, 1%
nonessential amino acids, 1% L-glutamine, 1 mM Na-
pyruvate, 100 U/mL penicillin, and 100 g/mL streptomycin.
The cells were grown in 100-mm tissue culture petri dishes
and passaged every 5 days at a split ratio of 1:5 and all cells
were maintained in an atmosphere of 5% CO2 and 90% rela-
tive humidity at 37°C. The medium in the cell culture cham-
bers was changed daily. Cells were used at passage numbers
37 to 45. Before reaching confluency, the cells were subcul-
tured with trypsin–ethylenediaminetetraacetic acid (0.25%,
0.02%) and seeded at a density of 3 × 105 cells per 25-mm
culture insert (3.0 M pore size). Cells were used between 2
to 3 weeks after seeding on to the inserts. The culture medium
was changed every other day for the first two weeks and once
a day thereafter. Cell integrity was evaluated by monitoring
Transepithelial Electrical Resistance (TEER) using an
EVOM Epithelial Voltohmmeter equipped with “chop-
stick” electrodes (World Precision Instruments, Sarasota, FL,
USA).
Subjects
All subjects gave written informed consent to participate
in the study that followed the tenets of the Declaration of
Helsinki promulgated in 1964 and was approved by the Insti-
tutional Review Board at the University of Michigan Medical
Center. All subjects were between the ages of 21–31 years and
were judged healthy based on medical history, physical ex-
amination, and laboratory tests prior to the study period.
CsA Transport Studies with Caco-2 Cells
Cells were used between 2 to 3 weeks after seeding on to
the inserts. Inserts containing the Caco-2 monolayers were
positioned in six-well plates such the outer surface of the
inserts (basolateral side) was immersed in the transport me-
dium. The general procedure for studying transport phenom-
ena of CsA in Caco-2 cells was as follows: All solutions and
buffers were pre-warmed at 37°C. The inserts containing
Caco-2 cells were washed twice with phosphate buffer (pH
7.4) before the transport study. The inserts were then im-
mersed into HEPES buffer, pH 7.4, with 2 mL on the top of
the membrane and 2.5 mL on the bottom. After equilibration
for 30 min, triplicate measurements of TEER values of the
inserts were undertaken. For the apical to basolateral side
transport studies (AP to BL), 1.5 ml of the test CsA transport
solution was placed on top of the insert (apical side of mem-
brane). CsA-free transport solution of an identical composi-
tion (2.5 mL) was placed on the bottom (basolateral side of
the membrane). Basolateral-to-apical side transport studies
(BL to AP) were performed by reversing the placement of the
test CsA and the CsA-free solutions. The solution from the
appropriate receiver compartment was collected in toto at
predetermined intervals for CsA assays, and was replaced by
an equal volume of fresh CsA-free transport solution. Test
transport solutions comprised 4.0 g/mL CsA containing
trace amount of 3H-CsA and varying amounts (0-2%w/v) of
either Cremophor EL or Cremophor RH40 or TPGS in
pH 7.4 HEPES buffer. Transport studies to determine the
effects of P-gp inhibitors on CsA transport were conducted
using solutions containing 0.4 g/ml or 4 mg/ml CsA with
trace amount of 3H-CsA, and 0-100 M of either verapamil,
progesterone, quinidine or chlorpromazine in pH 7.4 HEPES
buffer. At the end of the experiment, TEER values were
again measured in triplicate to establish effects of surfactants
on monolayer integrity. Non-specific binding of CsA to the
surface of the cell culture device was determined by soaking
the device in a solution containing 2% Cremophor EL fol-
lowed by mixing with EcoLite(+) that allowed dissolution of
the polystyrene treated plate and ascertaining that CsA re-
covery was complete. Appropriate amounts of EcoLite(+)
cocktail were added to all transport sample solutions as well
as pipet-tips, vortex mixed and assayed using a Beckman LS
6000 SC scintillation counter.
Human Jejunal Perfusion Studies
Subjects were admitted to the General Clinic Research
Center at the University of Michigan Medical Center on the
Chiu et al.750
day of the study at 7 am and fed a standard breakfast over the
next one and a half hours. A 5-mL blood sample was obtained
to determine the concentration of testosterone or estradiol.
The subjects remained fasted under supervision for the dura-
tion of the study, approximately 14 h. The intubation and
placement of the perfusion tube in the upper jejunum was
performed according to the procedure described previously
(11). The jejunal segment was first rinsed with 120–180 mL of
normal saline prewarmed to 37°C. The segment was then
perfused with the drug-containing solution pre-warmed to
37°C at a rate of 3 mL/min for 120 min. Sandimmune intra-
venous solution was used to prepare CsA perfusate solutions
since it was the only drug form of CsA approved for human
use that was available to us. Further, an additional 0.2% (w/v)
of Cremophor EL was incorporated in the perfusate solution
in order to prevent adsorption of CsA to the tubing. Thus, the
perfusate solution contained 4.2 M (5 g/mL) CsA, 0.2%
Cremophor EL, 12.3 mM PEG 400, 1.4 mM PEG 4000, 3.4
M dl-propranolol, 60.5 M l-phenylalanine, 10 mM d-
glucose, 5.4 mM KCl, 35.1 mM d-mannitol, 45 mM NaCl, 49
mM NaH2PO4·H2O, and 21 mM Na2HPO4. The final osmo-
lality and pH of the perfusate solution was adjusted to 290
mOsm/L and 6.5, respectively. The fluid leaving the intestinal
segment was collected on ice every 10 min by gravity drain-
age. During the entire study a vacuum pump (4 psi) was used
to facilitate continuous aspiration of accumulated gastric and
intestinal fluids in order to relieve bloating effects and also to
minimize their possible leakage into the perfused segment.
All syringes and samples were immediately weighed and the
samples were stored at −20°C until assay. All subjects re-
mained fasted and in a recumbent position until completion
of the perfusion study.
Drug Analysis
The concentrations of CsA, l-phenylalanine, dl-
propranolol, PEG 400, and PEG 4000 in human perfusion
study samples were assayed by high performance liquid chro-
matography (HPLC) methods. The HPLC system consisted
of a Waters interface module system, a Waters WISP™ 712
autosampler, a Waters 410 differential refractometer, a Wa-
ters 470 fluorescence detector, a Waters 996 photodiode array
detector, two Waters HPLC 515 pumps, a Waters 2.15 Mille-
nium chromatography manager system (Waters Corpora-
tion, Milford, MA, USA), and an Eppendorf CH-30 column
heater and TC-50 temperature controller (Eppendorf, West-
bury, NY, USA). CsA was assayed using previously reported
HPLC methods (17). Prior to extraction of CsA from perfus-
ate samples, 2% Tween 80 was incorporated in order to pre-
vent adsorption losses. CsA was extracted from the perfusate
by the following method. One ml of sample or standard was
mixed with 4 ml of ethyl acetate. It was then vortexed at 2000
rpm on a VXR shaker (Staufen, Germany) for 10 min. After
centrifuging for 10 min at 885 g, an amount of 3 mL solution
from the ethyl acetate layer was transferred using glass pi-
pettes and evaporated to dryness under nitrogen gas at the
room temperature. The residue was reconstituted with 200
L of 80% acetonitrile water (v/v) solution, vortexed, and
filtered through a 0.45-m syringe filter. An amount of 20 L
of reconstituted solution was then injected into HPLC for
assay (17). The recovery ratio of this extraction method was
85%. Propranolol was analyzed using a modification of a pre-
viously reported method (18). The modification involved the
use of mobile phase containing (16:4:80, v/v) of methanol,
tetrahydrofuran, and a buffer solution containing 1 g of
1-heptanesulfonic acid sodium salt, 15 mL of triethylamine
and 1000 ml of HPLC grade water. The pH of the buffer
solution was adjusted to 2.3 with concentrated phosphoric
acid, filtered and degassed before use. Analyses of PEG 400
and PEG 4000 were conducted using previously described
methods (11). CsA concentrations in Caco-2 cell studies were
determined by scintillation counting.
Data Analysis
Permeability Coefficients in Caco-2 Cells
The effective permeability value (Peff) was calculated
based on Fick’s law:
Peff = dQdtA * Co (1)
where dQ/dt is the flux across monolayer (dpm CsA/min); A
is the surface area of membrane (4.91 cm2); and C0 is the
initial drug concentration (dpm CsA/mL).
Estimation of Effective Permeability Coefficients in
Perfusion Studies
The effective permeability of the intestinal segment can
be calculated at steady state, typically achieved after about
30-40 min of perfusion, using mass balance on the perfusion
system as described previously (11).
dM
dt
= QCin − Cout = A  Peff  Cout (2)
where Cm is the inlet concentration of the drug and Cout is the
outlet concentration. Cout was assumed to be equal to the
concentration in the perfused jejunal tube segment because of
the assumption of complete mixing with the mixing tank
model (11). Peff is the effective permeability, Q is the volume
flow rate of the intestine and A ( 2RL) is the area of the
mass transfer surface of the jejunal segment. Rearranging Eq.
(1) in terms of Peff results in
Peff =
Q
A  CinCout − 1 = Q2RL  CinCout − 1 (3)
Cout/Cin is the fractional concentration of the drug adjusted
for the water transport determined using PEG 4000 (a non-










L is the length of the perfused segment (10 cm) and R is the
apparent individual radius of the segment. The individual seg-
mental radius was calculated using the segmental volume es-
timation as described earlier (11).
After calculation of effective permeability coefficients
from various human subjects with equation 3, a Z-score test
using three standard deviations as the exclusion criteria was
applied for outlier detection as in the previous study (11). The
effective permeability coefficients obtained after excluding
outliers were then normalized to a fixed segmental radius of
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1.75 cm. The mean of the normalized effective permeabilities
was then used to calculate fraction of drug absorbed.
Residence Time Distribution (RTD) Analysis
A noninteger mixing tank model was used to analyze the
residence time distribution as described previously (11). The
mean residence time and number of tanks in the perfused
segment were predicted from RTD analysis. The fractional
concentration curve (F curve) was calculated from the con-
centration of PEG 4000 by fitting the following equation:










n 1 −  rr − 1n−i+1 1i − 1! n + rt* ti−1 (5)
where F is the fraction of PEG 4000, n is the number of tanks,
r is the fraction tank, t is the time, and t* is the mean residence
time. The time (t) was calculated by subtracting the residence
time in the perfusion tubes, to account for the tube hold-up
time, and by using the mid-time during the 10-min sampling
collection period.
Statistical Analysis
Statistical analysis was performed using two-way analysis
of variance with Microsoft Excel 97.
RESULTS
Effects of Surfactants on CsA Transport in
Caco-2 Monolayers
The application of up to 2% (w/v) of Cremophor EL,
Cremophor RH40, or TPGS to either the apical or baso-
lateral side of Caco-2 monolayers for 2 h did not affect TEER
values significantly. The results suggest that the integrity of
the monolayers was maintained in the presence of the surfac-
tants. The effects of varying concentrations of surfactants on
the directional transport of CsA from perfusate solutions con-
taining 4 g/mL CsA are shown in Figs. 1–3. The results
indicate that in the absence of surfactants, the permeability of
CsA in the BL to AP direction is twice as high as that in the
AP-to-BL direction, suggesting net secretion. The permeabil-
ity of CsA decreased significantly with increasing surfactant
concentration in both AP-to-BL and BL-to-AP directions.
The magnitude of the decrease in permeability in either di-
rection was in the order Cremophor EL  Cremophor
RH40 >> TPGS.
Effects of P-gp Inhibitors on CsA Transport in
Caco-2 Monolayers
The effects of quinidine on the directional permeability
of CsA in Caco-2 monolayers at two different concentration
ratios are shown in Figs. 4 and 5. It is seen that when the
molar ratio of quinidine to CsA is low (3; Fig. 4), its effect on
CsA transport in either direction is not appreciably different
than the control. However, increasing the molar ratio to 300
(Fig. 5) resulted in a substantial enhancement in the transport
of CsA in the AP-BL direction and a significant reduction in
its transport in the BL-to-AP direction. These results appear
to be consistent with previous findings for a major role of
P-gp efflux mechanisms in determining CsA transport in
Caco-2 cells. Figure 6 shows a comparison of the enhance-
ment of CsA permeability in the AP-BL direction in the pres-
ence of the P-gp inhibitors quinidine, verapamil and proges-
Fig. 1. Effect of Cremophor EL concentration on directional per-
meability coefficient (mean ± SD) of cyclosporin A in Caco-2 mono-
layers. n  3. (BL-to-AP permeabilities significantly different from
each other; p < 0.05.)
Fig. 2. Effect of Cremophor RH 40 concentration on directional permeability coef-
ficient (mean ± SD) of cyclosporin A in Caco-2 monolayers. n  3. (BL-to-AP per-
meabilities significantly different from each other; p < 0.05.)
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terone, at a CsA to inhibitor molar ratio of 300. The results
indicate that the order of inhibition under these conditions
was quinidine > progesterone > verapamil.
Human Jejunal Perfusion Studies
RTD Analysis
F curve and outlet concentration vs. inlet concentration
of CsA and that of marker compounds showed that steady
state was achieved after 30 min. Thus, the F value of PEG
4000 was close to unity from 40 to 120 min. The mean resi-
dence time of PEG 4000 was estimated to be (mean ± sd) 7.3
± 5.5 min, the number of tanks 3.4 ± 3.2 and the recovery ratio
of PEG 4000 in all 12 subjects was 85% or higher.
Human Jejunal Permeability of CsA
The mean effective permeabilities of CsA and the refer-
ence markers phenylalanine, propranolol and PEG 400 esti-
mated using Eq. (3) and normalized to a fixed segmental
radius of 1.75 cm are shown in Table I. A comparison of the
normalized mean effective permeabilities of phenylalanine,
propranolol and PEG 400 in this study using perfusates con-
taining 0.2% Cremophor EL with previous estimates (11,12)
indicated no significant differences suggesting that Cremo-
phor EL does not influence the permeability of these com-
pounds (Table I).
DISCUSSION
The dramatic lowering of AP-to-BL (2 to 12-fold) per-
meabilities of CsA in the presence of surfactants suggests that
micellar solubilization of CsA decreases the fraction of “free”
unbound CsA that would be available for transport across the
monolayer. Thus, apparent permeabilities based on the total
CsA concentration would be substantially lower than the in-
trinsic permeability. Several previous studies examining the
effects of nonionic surfactants on transport in cell monolayers
have clearly indicated that the AP-to-BL transport of drugs
that are P-gp and/or MRP substrates increased at surfactant
concentrations at or below the critical micelle concentration
(19–22). These studies also showed decreased transport at
high surfactant concentrations as a result of micellar inclusion
of the drug. The critical micelle concentration (cmc) of Cre-
mophor EL has been reported to be 0.008%w/v (0.007–
0.009% w/v range) in Hanks balanced salt solution at pH 7.4
and 25°C (20), and 0.008% w/v in 0.05 M HEPES buffer, pH
7.0 (23). Further, the free fraction of paclitaxel, a drug that is
formulated in a manner similar to CsA, decreased from
around 94% at Cremophor EL concentrations below 0.01%
w/v to 46% and 18%, at Cremophor EL concentrations of
0.0625% and 0.25% w/v, respectively (23). Also, extensive
solubilization of tacrolimus in nonionic micelles has been re-
Fig. 4. Effect of 10 M quinidine on the directional permeability
coefficient (av ± SD) of cyclosporin A in Caco-2 monolayers. CsA
concentration  3.34 M (4.0 g/mL); n  3.
Fig. 5. Effect of 100 M quinidine on the directional permeability
coefficient (av ± SD) of cyclosporin A in Caco-2 monolayers. Cyclo-
sporin A concentration  0.334 M (0.4 g/ml); n  3. Permeability
in the presence of 100 M quinidine significantly different compared
with controls (p < 0.001).
Fig. 3. Effect of TPGS concentration on directional permeability coefficient (mean ±
SD) of cyclosporin A in Caco-2 monolayers. n  3. (BL-to-AP permeabilities signifi-
cantly different from each other; p < 0.05.)
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ported (24). It was found that the free fraction of tacrolimus
above the cmc of the HCO-60 nonionic surfactant was around
10–15%. The lack of enhancement in apparent AP-to-BL per-
meability of CsA in our studies may suggest that micellar
solubilization effects far outweigh any P-gp inhibitory effects
even at the lowest surfactant concentration of 0.02% w/v ex-
amined. Indeed, in studies with rhodamine 123 in Caco-2
monolayers, it was shown that the maximal levels of uptake in
the presence of various surfactants occurred in the proximity
of the respective cmc of the surfactant (22). Because the main
objective of these studies was to ascertain surfactant effects at
concentrations encountered in commercial CsA formulations,
detailed studies such as those described in previous studies
(20) were not conducted. Nevertheless, it appears that under
the conditions of our Caco-2 monolayer studies, the major
effect on AP-BL transport of CsA is caused by lowered CsA
activity arising out of micellization that results in lowered
apparent permeability coefficients. These effects are expected
to operate under in vivo conditions as well. The results in
Figs. 1–3 also indicate that such micellar solubilization effects
by surfactants in the basolateral compartment dramatically
lower BL-to-AP transport of CsA in Caco-2 monolayers. It is
not possible to ascertain if decreased efflux is due to micell-
ization alone or due to a combination of micellar solubiliza-
tion and inhibitory effects on P-gp efflux by the surfactants.
Previous studies on the effects of nonionic surfactants such as
Cremophor EL, Tween 60 and Pluronic 85, placed on the
apical side clearly demonstrated that the BL-AP transport of
a variety of P-gp substrates were significantly reduced reflect-
ing an inhibitory effect on P-gp efflux pump (19,21). It was
also shown that only monomers affected P-gp efflux and that
transport effects observed with surfactant concentrations
higher than the cmc were independent of the side of admin-
istration.
The results of the Caco-2 transport studies are consistent
with the following scenario. In the presence of surfactant con-
centrations that are much higher than the cmc, any enhance-
ment in CsA transport that might have resulted from inhibi-
tion of P-gp efflux mechanisms by surfactant monomers are
quite overwhelmed by the much larger negative effect of sur-
factant micelles on CsA transport. The net result of the two
opposing effects is to provide apparent permeability values
that are substantially lower than the intrinsic values.
The effective permeability of CsA in human jejunum
from perfusate solutions containing 0.2% w/v Cremophor
EL is therefore expected to be lower due to micellar solu-
bilization of CsA in Cremophor micelles. The Caco-2 trans-
port studies suggest that the apparent permeability in the
presence of 0.2% Cremophor EL or Cremophor RH40
could be reduced by a factor of 2 to 4 compared to that in the
absence of these surfactants. Thus, the intrinsic permeability
of CsA in humans could be substantially higher than the es-
timated mean normalized effective permeability value of 1.65
× 10−4 cm/s. The fraction dose absorbed calculated using a
permeability value of 1.65 × 10−4 cm/s, a mean residence time
of 3 h, and an intestinal radius of 1.75 cm was 0.87, suggesting
that CsA is a high permeability drug. The implications of the
overall effects of surfactants on the permeability of CsA in-
dicate that CsA could be classified as a BCS Class II low-
solubility, high-permeability drug (25). The high variability of
absorption characteristics from Sandimmune oral formula-
tions in humans may thus be due to other factors.
Sandimmune Oral CsA Formulation vs. Neoral Oral
CsA Formulation
The absorption of CsA from the conventional oral for-
mulation, Sandimmune is dependent on the presence of bile
in the gastrointestinal tract and is highly variable. The mean
absolute bioavailability of CsA from Sandimmune oral for-
mulations in humans has been reported to be around 30%
with very high inter- and intra-patient variability (4). The
absolute bioavailability of CsA (10 mg/kg) from Sandim-
mune oral formulations in healthy volunteers was reported
to be 23% in subjects fed a low fat diet and 42% in subjects
on a high fat diet (26). To obviate these problems, a novel
Table I. Normalized Mean Effective Permeabilities of Cyclosporin
A, and Various Reference Compounds Estimated Using Mean Ap-
parent Individual Segmental Radius and Normalized to a Fixed Ra-








Cyclosporin A 1.65 ± 0.53 0.32 12 –
Phenylalanine 4.54 ± 2.39 0.53 11 4.31 ± 2.11
Propranolol 2.90 ± 1.28 0.44 12 2.70 ± 1.19
PEG 400 0.83 ± 0.51 0.62 12 0.56 ± 0.38
a from Ref. 11.
Fig. 6. Comparison of enhancement in AP-to-BL transport of cyclosporin A in Caco-2
monolayers in the presence of various inhibitors. Inhibitor concentration  100 M;
cyclosporin A concentration  0.334 M (0.4 g/mL); n  3.
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microemulsion formulation of CsA was introduced (27). This
novel oral formulation, Neoral, contains corn oil mono-, di-,
and triglycerides, Cremophor RH40, glycerol, and propyl-
ene glycol in addition to CsA (100 mg/ml) and ethanol (9.5%
w/v). The absolute bioavailability of CsA from Neoral oral
formulations has not been determined yet. However, the rela-
tive bioavailability of CsA from Neoral formulations was
compared to that obtained from the Sandimmune oral for-
mulation in 48 healthy volunteers over the dosage range of
200 to 800 mg (27). It was found that both Cmax and systemic
availability (AUC) were greater for Neoral at all dose levels.
The enhancement in CsA oral bioavailability from Neoral
compared to that from Sandimmune ranged from 1.74 to
2.39 over the dosage range of 200 to 800 mg. Also, in contrast
to dose nonlinearity in CsA pharmacokinetics from Sandim-
mune oral formulations, dose proportionality in AUC re-
sponse was evident from the Neoral oral formulation. Inter-
estingly, the incidence of double peaks was found to be dra-
matically reduced at lower doses for the Neoral formulation
compared to Sandimmune (27). Several studies have also
shown that Cmax, tmax, and AUC for CsA after Neoral oral
administration are subject to less variability than with the
Sandimmune oral formulation (28). The absorption of CsA
from Neoral oral formulations in eleven de novo liver trans-
plant patients was found to be unaffected by T-tube diversion
of bile. Co-administration of food with Neoral oral formu-
lations was found to decrease AUC by 13%; however, there
were no differences between high fat and low fat meals. The
expectation of more consistent and superior clinical benefits
from Neoral oral formulations based on its superior phar-
macokinetics have been confirmed in several studies. Thus, in
renal transplantation, significant reductions in the incidence
of acute rejection (p  0.016), multiple rejection, treatment
failure in adult recipients (p  0.02), and in the incidence of
chronic rejection in pediatric recipients (p < 0.05) have been
reported (28). More importantly, it was found that there was
no increase in the incidence or severity of adverse effects in
transplant patients receiving continuous treatment with
Neoral for 2 years (28).
The superior absorption of CsA from Neoral oral for-
mulations compared with Sandimmune oral formulations
cannot be ascribed to differences in the effects of formulation
variables on P-gp efflux mechanisms. Although the two for-
mulations contain different surfactants, this appears to be a
reasonable conclusion based on the observations that micellar
solubilization effects far outweighed P-gp mediated effects on
absorption of CsA in Caco-2 studies. Further, the intrinsic
human jejunal permeability of CsA was quite high indicating
that intestinal permeability may not be the rate-limiting fac-
tor. Thus, other factors, such as dissolution characteristics of
CsA from the two formulations, may be involved. Particle size
is one of the key parameters that determines drug dissolution
from a given formulation. Indeed, the absolute bioavailability
of CsA from the Neoral oral microemulsion formulation
(particle size ∼40 nm) was determined to be about 3-fold
higher than that obtained following oral administration of the
Sandimmune oral formulation (particle size ∼860 nm) in rats
(29). The role of particle size rather than of surfactant type
was also evidenced in their study. Thus, it was found that
absolute bioavailabilities similar to that obtained with the
Neoral oral formulation were observed using a microemul-
sion formulation containing Cremophor EL, Captex 355,
and Transcutol comparable in size (∼20 nm) to the Neoral
formulation (29). The bioavailability of CsA in rabbits fol-
lowing oral administration of a lecithin-based liposomal for-
mulation (particle size ∼60 nm) was found to be similar to that
obtained following oral administration of the Neoral oral
formulation (30). The enhanced absorption from formula-
tions with much smaller particle sizes are consistent with the
classic use of micronization of dosage forms to improve area
under the concentration-time curve (AUC) when compared
with the original formulation.
CONCLUSIONS
The presence of 0.2% (w/v) of the noinionic surfactant
Cremophor EL decreased apical-to-basolateral transport of
CsA in Caco-2 monolayers about 2- to 3-fold compared with
that observed in the absence of surfactant. These effects ap-
pear to be modulated mainly via micellar solubilization of
CsA, thereby reducing thermodynamic activity of CsA and its
permeability. It is also possible that the surfactants inhibit
P-gp efflux in these models and increase permeability of CsA;
however, micellar solubilization effects far outweigh P-gp-
mediated increases resulting in a net overall reduction in CsA
permeability. Similar reductions in intrinsic permeability of
CsA in the presence of surfactants are also expected in human
perfusion studies. Thus, the intrinsic CsA permeability in hu-
mans is likely to be about two to 3-fold higher than the esti-
mate of 1.65 × 10−4 cm/s from perfusion studies containing
0.2% (w/v) Cremophor EL. Thus, the intrinsic permeability
of CsA is expected to be high and it can rightly be classified
as a BCS Class II high permeability-low solubility drug. The
highly variable absorption of CsA from Sandimmune oral
formulations in humans appears to be related to the poor
dissolution characteristics of the drug.
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